Gadobutrol

Gadobutrol

Systematic (IUPAC) name
gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Clinical data
AHFS/Drugs.com	International Drug Names
Licence data	US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	IV
Identifiers
CAS Number	138071-82-6
ATC code	V08CA09
PubChem	CID 72057
DrugBank	DB06703
UNII	1BJ477IO2L
KEGG	D07420
ChEBI	CHEBI:68841
ChEMBL	CHEMBL1628503
Chemical data
Formula	C18H31GdN4O9
Molar mass	604.710 g/mol
SMILES C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Ga+3]
(what is this?)  (verify)

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

It received marketing approval in Canada^[1] and in the United States.^[2][3][4]

As of 2007, it was the only GBCA approved at 1.0 molar concentrations.^[5]

Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.^[6]

References

1. Cheng, KT (2007). Gadobutrol (PDF). Molecular Imaging and Contrast Agent Database (MICAD) (Bethesda, MD: National Center for Biotechnology Information (NCBI)). PMID 20641787. NBK23589.
2. "Bayer in Radiology - Gadavist® (gadobutrol) injection 1 mmol/mL". bayerimaging.com. Retrieved 20 May 2015.
3. "FDA approves imaging agent for central nervous system scans" (Press release). U.S. Food and Drug Administration (FDA). March 15, 2011. Retrieved March 31, 2011.
4. "U.S. FDA Approves Bayer’s Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System" (Press release). Bayer HealthCare Pharmaceuticals. March 14, 2011. Retrieved March 31, 2011.
5. "Education for Cardiology Disease Professionals - Radcliffecardiology" (PDF). touchcardiology.com. Retrieved 20 May 2015.
6. "Gadavist full prescribing information" (PDF). Retrieved 2011-03-14.